Karyopharm Therapeutics Inc. (KPTI) Given “Outperform” Rating at Leerink Swann
A number of other research analysts have also recently issued reports on KPTI. Canaccord Genuity set a $20.00 price target on shares of Karyopharm Therapeutics and gave the company a buy rating in a research report on Saturday, August 6th. Wedbush reissued an outperform rating and set a $14.00 price target on shares of Karyopharm Therapeutics in a research report on Friday, June 10th. Zacks Investment Research cut shares of Karyopharm Therapeutics from a hold rating to a sell rating in a research report on Tuesday, July 12th. Vetr cut shares of Karyopharm Therapeutics from a strong-buy rating to a buy rating and set a $11.00 price target for the company. in a research report on Wednesday, August 31st. Finally, Jefferies Group restated a buy rating and issued a $12.00 price target on shares of Karyopharm Therapeutics in a research report on Thursday, September 8th. Two analysts have rated the stock with a sell rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $16.04.
Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded up 4.132% during mid-day trading on Friday, hitting $9.955. 94,956 shares of the company were exchanged. The company has a 50 day moving average of $9.09 and a 200 day moving average of $8.41. The company’s market capitalization is $358.27 million. Karyopharm Therapeutics has a 52 week low of $4.83 and a 52 week high of $19.41.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by $0.08. Equities analysts anticipate that Karyopharm Therapeutics will post ($3.22) earnings per share for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Metropolitan Life Insurance Co. NY bought a new position in Karyopharm Therapeutics during the second quarter worth approximately $136,000. Nationwide Fund Advisors boosted its position in Karyopharm Therapeutics by 38.3% in the second quarter. Nationwide Fund Advisors now owns 21,258 shares of the company’s stock worth $143,000 after buying an additional 5,886 shares during the last quarter. ProShare Advisors LLC boosted its position in Karyopharm Therapeutics by 1.3% in the second quarter. ProShare Advisors LLC now owns 29,655 shares of the company’s stock worth $199,000 after buying an additional 376 shares during the last quarter. Highbridge Capital Management LLC bought a new position in Karyopharm Therapeutics during the second quarter worth approximately $200,000. Finally, Alliancebernstein L.P. boosted its position in Karyopharm Therapeutics by 24.2% in the second quarter. Alliancebernstein L.P. now owns 34,930 shares of the company’s stock worth $234,000 after buying an additional 6,800 shares during the last quarter. Hedge funds and other institutional investors own 55.71% of the company’s stock.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.